Nektar Therapeutics Reports That Pfizer Inc. Announced New Analyses Showing That Exubera Is Effective in Diabetes Patients Who Have Respiratory Infections Or Who Are Exposed To Passive Cigarette Smoke

Nektar Therapeutics (Nasdaq:NKTR) reported today that Pfizer announced that new Exubera(R) (insulin human (rDNA origin)) Inhalation Powder data were being presented today at the 42nd European Association for the Study of Diabetes. Pfizer announced that adult patients with diabetes who took Exubera were able to safely maintain good blood sugar control even if they developed a respiratory infection or were exposed to passive (second-hand) cigarette smoke. Retrospective analyses of 14 Exubera Phase II and III clinical studies showed Exubera was well tolerated and efficacious, even during respiratory illness in adults with type 1 or type 2 diabetes. Another new study found that while passive smoke exposure could result in decreased absorption, Exubera could be used by adult patients who were exposed to a smoky environment.

Back to news